Extracellular Vesicle Therapy for Type 1 Diabetes
Overview
Authors
Affiliations
Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation.
Forkan C, Shrestha A, Yu A, Chuang C, Pociot F, Yarani R Stem Cell Res Ther. 2025; 16(1):37.
PMID: 39901225 PMC: 11792614. DOI: 10.1186/s13287-025-04153-4.
The Potential of Mesenchymal Stem Cell-Derived Exosomes to Treat Diabetes Mellitus.
Kim J, Lee J, Cha G, Yoon J Biomimetics (Basel). 2025; 10(1).
PMID: 39851765 PMC: 11760843. DOI: 10.3390/biomimetics10010049.
Engineered extracellular vesicles as "supply vehicles" to alleviate type 1 diabetes.
Wang F, Li Z Extracell Vesicles Circ Nucl Acids. 2025; 5(4):718-721.
PMID: 39811729 PMC: 11725422. DOI: 10.20517/evcna.2024.61.
Dekkers M, Pu X, Enciso-Martinez A, Zaldumbide A Cells. 2024; 13(23).
PMID: 39682744 PMC: 11640590. DOI: 10.3390/cells13231996.
Njoku G, Forkan C, Soltysik F, Nejsum P, Pociot F, Yarani R Bioact Mater. 2024; 45:41-57.
PMID: 39610953 PMC: 11602541. DOI: 10.1016/j.bioactmat.2024.11.004.